Harvard
Lindström, U, Di Giuseppe, D, Delcoigne, B
, Glintborg, B, Möller, B, Ciurea, A, Pombo-Suarez, M, Sanchez-Piedra, C, Eklund, K, Relas, H, Gudbjornsson, B, Love, TJ, Jones, GT, Codreanu, C, Ionescu, R, Nekvindova, L, Závada, J, Atas, N, Yolbas, S, Fagerli, KM, Michelsen, B, Rotar, Ž, Tomšič, M, Iannone, F, Santos, MJ, Avila-Ribeiro, P
, Ørnbjerg, LM, Østergaard, M, Jacobsson, LT, Askling, J & Nissen, MJ 2021, '
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration',
Annals of the Rheumatic Diseases, bind 80, nr. 11, s. 1410-1418.
https://doi.org/10.1136/annrheumdis-2021-220097APA
Lindström, U., Di Giuseppe, D., Delcoigne, B.
, Glintborg, B., Möller, B., Ciurea, A., Pombo-Suarez, M., Sanchez-Piedra, C., Eklund, K., Relas, H., Gudbjornsson, B., Love, T. J., Jones, G. T., Codreanu, C., Ionescu, R., Nekvindova, L., Závada, J., Atas, N., Yolbas, S., ... Nissen, M. J. (2021).
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Annals of the Rheumatic Diseases,
80(11), 1410-1418.
https://doi.org/10.1136/annrheumdis-2021-220097CBE
Lindström U, Di Giuseppe D, Delcoigne B
, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P
, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ. 2021.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Annals of the Rheumatic Diseases. 80(11):1410-1418.
https://doi.org/10.1136/annrheumdis-2021-220097MLA
Vancouver
Author
Lindström, Ulf ; Di Giuseppe, Daniela ; Delcoigne, Bénédicte
; Glintborg, Bente ; Möller, Burkhard ; Ciurea, Adrian ; Pombo-Suarez, Manuel ; Sanchez-Piedra, Carlos ; Eklund, Kari ; Relas, Heikki ; Gudbjornsson, Bjorn ; Love, Thorvardur Jon ; Jones, Gareth T ; Codreanu, Catalin ; Ionescu, Ruxandra ; Nekvindova, Lucie ; Závada, Jakub ; Atas, Nuh ; Yolbas, Servet ; Fagerli, Karen Minde ; Michelsen, Brigitte ; Rotar, Žiga ; Tomšič, Matija ; Iannone, Florenzo ; Santos, Maria Jose ; Avila-Ribeiro, Pedro
; Ørnbjerg, Lykke Midtbøll ; Østergaard, Mikkel ; Jacobsson, Lennart Th ; Askling, Johan ; Nissen, Michael J. /
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. I:
Annals of the Rheumatic Diseases. 2021 ; Bind 80, Nr. 11. s. 1410-1418.
Bibtex
@article{b8c34b543af24c08be7a19f63998aa89,
title = "Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration",
abstract = "BACKGROUND: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy.METHODS: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed.RESULTS: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept.CONCLUSION: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab.",
keywords = "Adalimumab/therapeutic use, Adult, Antirheumatic Agents/therapeutic use, Arthritis, Psoriatic/drug therapy, Drug Therapy, Combination, Etanercept/therapeutic use, Female, Humans, Infliximab/therapeutic use, Male, Methotrexate/therapeutic use, Middle Aged, Remission Induction, Treatment Outcome, Tumor Necrosis Factor Inhibitors/therapeutic use",
author = "Ulf Lindstr{\"o}m and {Di Giuseppe}, Daniela and B{\'e}n{\'e}dicte Delcoigne and Bente Glintborg and Burkhard M{\"o}ller and Adrian Ciurea and Manuel Pombo-Suarez and Carlos Sanchez-Piedra and Kari Eklund and Heikki Relas and Bjorn Gudbjornsson and Love, {Thorvardur Jon} and Jones, {Gareth T} and Catalin Codreanu and Ruxandra Ionescu and Lucie Nekvindova and Jakub Z{\'a}vada and Nuh Atas and Servet Yolbas and Fagerli, {Karen Minde} and Brigitte Michelsen and {\v Z}iga Rotar and Matija Tom{\v s}i{\v c} and Florenzo Iannone and Santos, {Maria Jose} and Pedro Avila-Ribeiro and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Mikkel {\O}stergaard and Jacobsson, {Lennart Th} and Johan Askling and Nissen, {Michael J}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. COPECARE",
year = "2021",
month = nov,
doi = "10.1136/annrheumdis-2021-220097",
language = "English",
volume = "80",
pages = "1410--1418",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "11",
}
RIS
TY - JOUR
T1 - Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
AU - Lindström, Ulf
AU - Di Giuseppe, Daniela
AU - Delcoigne, Bénédicte
AU - Glintborg, Bente
AU - Möller, Burkhard
AU - Ciurea, Adrian
AU - Pombo-Suarez, Manuel
AU - Sanchez-Piedra, Carlos
AU - Eklund, Kari
AU - Relas, Heikki
AU - Gudbjornsson, Bjorn
AU - Love, Thorvardur Jon
AU - Jones, Gareth T
AU - Codreanu, Catalin
AU - Ionescu, Ruxandra
AU - Nekvindova, Lucie
AU - Závada, Jakub
AU - Atas, Nuh
AU - Yolbas, Servet
AU - Fagerli, Karen Minde
AU - Michelsen, Brigitte
AU - Rotar, Žiga
AU - Tomšič, Matija
AU - Iannone, Florenzo
AU - Santos, Maria Jose
AU - Avila-Ribeiro, Pedro
AU - Ørnbjerg, Lykke Midtbøll
AU - Østergaard, Mikkel
AU - Jacobsson, Lennart Th
AU - Askling, Johan
AU - Nissen, Michael J
N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
COPECARE
PY - 2021/11
Y1 - 2021/11
N2 - BACKGROUND: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy.METHODS: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed.RESULTS: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept.CONCLUSION: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab.
AB - BACKGROUND: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy.METHODS: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed.RESULTS: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept.CONCLUSION: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab.
KW - Adalimumab/therapeutic use
KW - Adult
KW - Antirheumatic Agents/therapeutic use
KW - Arthritis, Psoriatic/drug therapy
KW - Drug Therapy, Combination
KW - Etanercept/therapeutic use
KW - Female
KW - Humans
KW - Infliximab/therapeutic use
KW - Male
KW - Methotrexate/therapeutic use
KW - Middle Aged
KW - Remission Induction
KW - Treatment Outcome
KW - Tumor Necrosis Factor Inhibitors/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85107521561&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2021-220097
DO - 10.1136/annrheumdis-2021-220097
M3 - Journal article
C2 - 34083206
VL - 80
SP - 1410
EP - 1418
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 11
ER -
